Ethan Weiner

During the course of his career, Dr. Weiner has been involved in all aspects of drug and biologics development. This work spanned early and late phases of development and involved working with discovery and commercial organizations to create therapeutic area strategies, product profiles, and development plans, achieving profiles for specific molecules.

Dr. Weiner supported the in-licensing and out-licensing of multiple drug candidates, and he is experienced in several therapeutic areas (inflammation, pain, infectious diseases, pulmonary diseases, ophthalmology, and oncology) across multiple geographic regions, including Japan, Asia, North America, and Europe.

Dr. Weiner obtained his M.D. from The Johns Hopkins University School of Medicine, Baltimore, Maryland.

Suggested For You

webinar

December 4th, 2025

Writing with Quality Control in Mind: A Cross-functional Approach 

webinar

June 26th, 2025

De-Risking Development with Specialized Data Strategies: From Trial Design to Submission

perspectives

November 4th, 2025

4 Key Takeaways from the EMA - Health Canada Joint Review Process and Evaluation of Its Efficiency

perspectives

October 28th, 2025

New Updates on Clinical Trial Transparency and Regulatory Requirements: A Comprehensive Overview 

webinar

October 21st, 2025

A Practical Guide to Expedited Regulatory Pathways

perspectives

October 21st, 2025

Shaping Clinical Development Through Writing: Francesca’s Journey at MMS 

news

October 16th, 2025

MMS Named Finalist in the Fierce Life Sciences Innovation Awards for KerusCloud® Clinical Trial Simulation Platform 

perspectives

October 14th, 2025

CRO Partnerships and Biotech Agility: How Smaller Sponsors Gain Speed in Clinical Development  

perspectives

October 7th, 2025

From Academia to Building Medical Writing Partnerships: Jessica Murdock’s MMS Story  

news

October 2nd, 2025

MMS Announces Its Role in Supporting Gates Ventures and the GNPC to Deliver One of the World's Largest Proteomic Datasets for Neurodegenerative Diseases

perspectives

September 30th, 2025

Ready by Design: Endpoints, Feasibility, and Scenario Testing

news

September 24th, 2025

MMS Named Finalist in Citeline’s 2025 Scrip Awards for Best Contract Research Organization (CRO) – Specialist Providers